| $385M | ||
| $350M | ||
| $215M | ||
| $82M | ||
| $76M | ||
| $62M |
Buys | $23,993,224 | 1 | 6 |
Sells | $10,449,605 | 15 | 94 |
| BAKER BROS. ADVISORS LP | director | 1 | $23.99M | 0 | $0 | $23.99M |
| GOLL JOHN | SVP, FINANCE & CAO | 0 | $0 | 1 | $22,580 | $-22,580 |
| St Leger Tina Amber | CHIEF HR OFFICER | 0 | $0 | 1 | $32,350 | $-32,350 |
| Jallal Bahija | CHIEF EXECUTIVE OFFICER | 0 | $0 | 1 | $371,184 | $-371,184 |
| Berman David M | HEAD OF R&D | 0 | $0 | 12 | $10.02M | $-10.02M |
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers. In addition, the company's programs for infectious diseases include IMC-I109V, which is in a Phase I/II clinical trial in patients with chronic hepatitis B virus; and IMC-M113V that is in pre-clinical development stage for patients with human immunosuppression virus. Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
Over the last 12 months, insiders at Immunocore Holdings plc have bought $23.99M and sold $10.45M worth of Immunocore Holdings plc stock.
On average, over the past 5 years, insiders at Immunocore Holdings plc have bought $23.99M and sold $6.48M worth of stock each year.
Highest buying activity among insiders over the last 12 months: BAKER BROS. ADVISORS LP (director) — $23.99M.
The last purchase of 807,338 shares for transaction amount of $23.99M was made by BAKER BROS. ADVISORS LP (director) on 2025‑03‑17.
| 2026-02-18 | Sale | Jallal Bahija | CHIEF EXECUTIVE OFFICER | 11,474 0.0226% | $32.35 | $371,184 | +0.17% | |
| 2026-02-18 | Sale | Berman David M | HEAD OF R&D | 5,965 0.0118% | $32.35 | $192,968 | +0.17% | |
| 2026-02-18 | Sale | St Leger Tina Amber | CHIEF HR OFFICER | 1,000 0.002% | $32.35 | $32,350 | +0.17% | |
| 2026-02-18 | Sale | GOLL JOHN | SVP, FINANCE & CAO | 698 0.0014% | $32.35 | $22,580 | +0.17% | |
| 2025-12-05 | Sale | Berman David M | HEAD OF R&D | 572 0.0012% | $40.14 | $22,960 | -14.23% | |
| 2025-12-04 | Sale | Berman David M | HEAD OF R&D | 31,341 0.0622% | $40.26 | $1.26M | -17.19% | |
| 2025-11-28 | Sale | Berman David M | HEAD OF R&D | 5,521 0.0111% | $40.09 | $221,337 | -15.42% | |
| 2025-11-26 | Sale | Berman David M | HEAD OF R&D | 69,404 0.1375% | $40.12 | $2.78M | -16.63% | |
| 2025-11-25 | Sale | Berman David M | HEAD OF R&D | 18,020 0.0363% | $40.03 | $721,341 | -15.99% | |
| 2025-11-24 | Sale | Berman David M | HEAD OF R&D | 100 0.0002% | $40.00 | $4,000 | -13.33% | |
| 2025-09-30 | Sale | Berman David M | HEAD OF R&D | 61,849 0.1191% | $35.23 | $2.18M | -7.14% | |
| 2025-09-15 | Sale | Berman David M | HEAD OF R&D | 200 0.0004% | $35.01 | $7,002 | -1.92% | |
| 2025-09-12 | Sale | Berman David M | HEAD OF R&D | 22,532 0.0453% | $35.67 | $803,699 | -4.20% | |
| 2025-09-11 | Sale | Berman David M | HEAD OF R&D | 19,081 0.0376% | $36.28 | $692,259 | -7.68% | |
| 2025-09-10 | Sale | Berman David M | HEAD OF R&D | 31,338 0.0618% | $36.14 | $1.13M | -7.25% | |
| 2025-03-17 | BAKER BROS. ADVISORS LP | director | 807,338 1.5953% | $29.72 | $23.99M | +9.85% | ||
| 2024-04-01 | Sale | St Leger Tina Amber | CHIEF HR OFFICER | 4,375 0.0171% | $64.06 | $280,263 | -47.08% | |
| 2024-02-28 | Sale | Berman David M | HEAD OF R&D | 36,509 0.1529% | $68.59 | $2.5M | -49.72% | |
| 2024-02-27 | Sale | Berman David M | HEAD OF R&D | 54,938 0.2377% | $70.86 | $3.89M | -50.15% | |
| 2024-02-26 | Sale | Berman David M | HEAD OF R&D | 28,553 0.1232% | $70.65 | $2.02M | -50.06% |
| Increased Positions | 82 | +61.19% | 6M | +11.34% |
| Decreased Positions | 51 | -38.06% | 3M | -6.08% |
| New Positions | 33 | New | 3M | New |
| Sold Out Positions | 11 | Sold Out | 186,642 | Sold Out |
| Total Postitions | 165 | +23.13% | 52M | +5.26% |
| T. Rowe Price Investment Management, Inc. | $238,618.00 | 13.85% | 7.06M | -3,763 | -0.05% | 2025-09-30 |
| Rtw Investments, Lp | $164,502.00 | 9.55% | 4.87M | 0 | 0% | 2025-09-30 |
| Wellington Management Group Llp | $161,498.00 | 9.37% | 4.78M | +567,314 | +13.46% | 2025-09-30 |
| Fmr Llc | $149,321.00 | 8.67% | 4.42M | -435,369 | -8.97% | 2025-09-30 |
| Primecap Management Co/Ca/ | $126,829.00 | 7.36% | 3.75M | -16,914 | -0.45% | 2025-09-30 |
| Bellevue Group Ag | $94,476.00 | 5.48% | 2.8M | +354,973 | +14.54% | 2025-09-30 |
| Baker Bros. Advisors Lp | $78,459.00 | 4.55% | 2.32M | 0 | 0% | 2025-09-30 |
| Tang Capital Management Llc | $77,883.00 | 4.52% | 2.31M | +200,000 | +9.5% | 2025-09-30 |
| Deep Track Capital, Lp | $60,804.00 | 3.53% | 1.8M | 0 | 0% | 2025-09-30 |
| Bvf Inc/Il | $53,179.00 | 3.09% | 1.57M | +550,000 | +53.7% | 2025-09-30 |